Welcome to our dedicated page for Senestech news (Ticker: SNES), a resource for investors and traders seeking the latest updates and insights on Senestech stock.
SenesTech, Inc. develops and commercializes fertility-control products for managing animal pest populations, with current products focused on rat and mouse populations. Its product names include ContraPest, Evolve Rat, and Evolve Mouse, which are used within pest-management programs as alternatives or complements to traditional rodent-control methods.
Company news centers on Evolve commercialization, e-commerce and direct-to-consumer sales channels, Amazon marketplace management, field-study data on rodent activity, product approvals in international markets, quarterly and annual financial results, capital runway commentary, and executive leadership or board governance updates.
SenesTech, Inc. (NASDAQ: SNES) announced the election of three new directors to its Board to bolster support for the commercial growth of ContraPest®, its lead fertility control product. Phil Grandinetti, K.C. Kavanagh, and Jake Leach bring diverse skills in consumer products, communications, and technology, respectively. The transition includes Dr. Julie Williams stepping down but remaining as Director Emeritus. SenesTech aims to redefine pest management by targeting reproduction in pest populations, reducing reliance on traditional lethal methods.
SenesTech, Inc. (NASDAQ: SNES) will announce its third quarter 2020 financial results on November 11, 2020. The announcement will follow the market close, accompanied by a conference call at 5:00 pm ET. The company focuses on innovative pest management solutions through fertility control, particularly its product ContraPest, aimed at reducing rat populations. This method targets the reproductive capabilities of rats, presenting a non-lethal alternative to traditional pest control.
SenesTech, Inc. (NASDAQ: SNES) announced that California's AB1788, signed by Governor Gavin Newsom, will become law on January 1, 2021. This law prohibits the use of certain Second Generation Anticoagulant Rodenticides (SGARs) in many contexts. As pest management professionals adapt to these changes, SenesTech's ContraPest fertility control technology is positioned to replace SGARs, showing effectiveness in reducing rodent populations by 60% to 90%. SenesTech plans to enhance awareness and adoption of ContraPest in California's pest management market, a sector valued at approximately $100 million annually.
SenesTech (NASDAQ: SNES) announced that ContraPest® has been added to San Francisco's Reduced Risk Pesticide List, allowing for its broader use in the city. This addition signifies a pivotal step in pest management, as ContraPest targets rat populations through fertility control, showcasing effectiveness and environmental safety. The city's ongoing efforts align with California's move away from harmful rodenticides, with ContraPest touted as a critical component of integrated pest management (IPM) strategies. Successful trials in San Francisco parks suggest an imminent expansion of ContraPest's usage.
SenesTech, Inc. (NASDAQ: SNES) will participate in the Lytham Partners Virtual Investor Growth Conference on October 7, 2020, at 12:00pm ET. The conference will feature a presentation and fireside chat, followed by virtual one-on-one meetings with management. SenesTech focuses on innovative pest management through its product, ContraPest®, aimed at controlling rat populations non-lethally. The webcast will be available on SenesTech's investor relations website, with a replay accessible post-event.
SenesTech, Inc. (NASDAQ: SNES) announced that California's AB1788 has passed the Legislature and is awaiting the Governor's signature. This bill aims to restrict the use of Second Generation Anticoagulant Rodenticides, impacting pest management strategies. SenesTech's fertility control product, ContraPest®, is highlighted as an effective alternative in integrated pest management (IPM) programs across diverse environments, positioning the company favorably amid regulatory changes. The team emphasizes collaboration with pest management professionals to adapt to this evolving landscape.
SenesTech, Inc. (NASDAQ: SNES) reported its second-quarter fiscal 2020 results, highlighting significant revenue growth, reaching approximately $71,000 compared to $24,000 in Q2 2019. The company made strides in pilot programs for municipal and poultry industries and created a direct-to-consumer online platform. Despite a net loss of $(1.6) million, an improvement from $(2.3) million in the prior year, operational projects continued amid COVID-19 challenges. Key partnerships, including deployment of ContraPest in Washington D.C., were confirmed for wider application as budgets permit.
On August 12, 2020, SenesTech, Inc. (NASDAQ: SNES) announced the San Francisco Recreation and Parks Department's success using its fertility control product, ContraPest, which was integrated into their pest management strategies in 2019. The program has reportedly led to a 65% reduction in burrow counts, showcasing a significant impact on rodent populations without harming the environment. ContraPest targets reproduction in both male and female rats, promoting an eco-friendly alternative to traditional rodenticides.
SenesTech, Inc. (NASDAQ: SNES) will announce its second quarter 2020 financial results after the market closes on August 12, 2020. A conference call is scheduled for the same day at 5:00 pm ET to discuss these results. The company focuses on innovative pest management with its product ContraPest®, which targets rat reproduction. This technology aims to reduce reliance on lethal pest control methods.